Stocks · News reference
Aptar Collaborates With Massachusetts General Hospital To Advance Nose-To-Brain Drug Delivery And Accelerate CNS Pipelines
Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelinesAptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Initiates Coverage On AptarGroup with Neutral Rating, Announces Price Target of $135
AptarGroup’s Russian Subsidiary Placed Under Temporary External Administration By Kremlin Decree; Says Aptar Vladimir Represented Less Than 0.6% Of Net Sales And Operating Income As Of Dec 31, 2025
AptarGroup, Inc. (the "Company") takes note of the decree of the President of the Russian Federation, published on September 21, 2026, that places the Company’s Russian subsidiary, OOO Aptar Vladimir ("Aptar
8-K filing — APTARGROUP, INC. (ATR)
Filed: 2026-09-21 AccNo: 0001104659-26-109359 Size: 191 KB Item 7.01: Regulation FD Disclosure